John Goldberg, MD
Infectious Disease · Tempe, AZNPI 1356319388
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 63.1% of it on its own, with 6 other manufacturers making up the rest.
Across 20 payments — averaging $52.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$660
- Alkermes, Inc.$125
- Shionogi Inc$108
- Astellas Pharma US Inc$96
- Takeda Pharmaceuticals U.S.A., Inc.$24
- Boehringer Ingelheim$19
- plus $14 from 1 others
What the payments were for
- Food & beverage$94991%
- Education$969%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $660 |
| Alkermes, Inc. | 1 | $125 |
| Shionogi Inc | 1 | $108 |
| Astellas Pharma US Inc | 3 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- EMBLAVEO$147
- ARISTADA INITIO$125
- AVYCAZ$121
- Fetroja$108
How this compares
$1,046 in reported general payments places this provider in the 75th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 43 | $26,568 |
| ErtapenemErtapenem Sodium | 39 | $9,892 |
| Vancomycin Hcl | 60 | $6,198 |
| Meropenem | 16 | $3,485 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 40 | $2,548 |
| Cefazolin Sodium | 20 | $1,655 |
| Sodium Chloride0.9 % Sodium Chloride | 16 | $1,269 |
| Fluconazole | 32 | $1,249 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 91 | $1,077 |
| Doxycycline Hyclate | 73 | $592 |
| Clindamycin Hcl | 23 | $494 |
| CeftriaxoneCeftriaxone Sodium | 21 | $445 |
| CefuroximeCefuroxime Axetil | 45 | $434 |
| Ciprofloxacin Hcl | 28 | $230 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tempe
- Thanes VanigPhoenix$258K
- Anita KohliChandler$213K
- Vipul GanatraPhoenix$151K
- Jorge MeraNogales$101K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Edward CachayScottsdale$26K
- Aman DalalScottsdale$22K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.